PK/PD and Tolerability Testing in the ADPKD Mouse Model

PK/PD and Tolerability Testing in the ADPKD Mouse Model

The lead optimisation phase is a crucial process during which you investigate and select the most promising preclinical candidate(s) to progress to efficacy testing using animal models of human diseases. Pharmacokinetic (PK) and Pharmacodynamic (PD) profiling helps...
PK/PD and Tolerability Testing in the ADPKD Mouse Model

The Application of Cystic Index in the ADPKD Mouse Model 

The kidneys of autosomal dominant polycystic kidney disease (ADPKD) patients progressively enlarge due to the formation and expansion of fluid-filled cysts. However, currently there is no available therapy for ADPKD patients that targets the growth of cysts,...
How to ensure that you are working with translationally relevant kidney disease research models? 

Validated Transdermal GFR Measurement in Kidney Disease Models

At InnoSer, we offer several readouts to assess the disease progression and the efficacy of novel targeted polycystic kidney disease (PKD) compounds. However, we understand that it remains a significant challenge to access crucial readouts that are recognized by...